Investor Presentaiton

REGULATORY ENVIRONMENT ACTIVITY Australia: MRI Licences • • • • • . ☐ On 1 November 2022 the Federal government de-regulated MRI services in regional and rural areas, defined as Modified Monash Model 2-7. As at the date of this presentation no further licences or plans for deregulation of MRI licences have been announced FY 2022 Medicare Changes Indexation of 1.6% announced and applied to 97% of Diagnostic Imaging Services, including MRI items, from 1 July 2022, well below inflation Bulk billing incentive on MRI reduced to 95% of CMBS from 100% from 1 July 2022. This only affects MRI services currently bulk billed to Medicare From 1 November 2021, new PET item introduced for the diagnosis of Alzheimer's Disease. Time restrictions on CT scans for colorectal studies removed. MRI for breast biopsy changed to allow for co-claiming with ultrasound and biopsy items. MRI for prostate cancer item description now includes an expanded population to allow high risk patients access to this service From 1 July 2022, two new PET items introduced for patients with prostate cancer. These items allow for the initial staging of intermediate to high-risk patients with prostate cancer New Zealand: There is limited indexation of pricing in New Zealand, however we continue to negotiate with a range of funders Emerging market practices continue to be challenging in New Zealand where referrers are acquiring ownership interests in radiology practices or equipment. IDX is working with the New Zealand Institute of Independent Radiologists, to encourage New Zealand payors and regulators to review these practices against their published guidelines on non-arm's length referrals and will undertake the necessary actions to manage referrer conflicts of interest. IDX supports the upholding of the current published guidelines to ensure that quality is maintained, that patient choice is retained, and that payors are not subject to over-servicing and unnecessary imaging. IDX is also developing its referrer base in the New Zealand general practitioner market, a market segment that is less impacted by non-arms length referrals idx

View entire presentation